HGHui Gong

Hui Gong

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hui Gong has a total of 162 co-authors. Here are the top co-authors by number of shared publications:

  • Yunzeng Zou

    Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital and Institutes of Biomedical Sciences, Fudan University, Shanghai, China

    21 shared publications
  • Ying Wang

    Shanghai Institute of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Diseases, Zhongshan Hospital and Institutes of Biomedical Sciences, NHC Key Laboratory of Ischemic Heart Diseases, Key Laboratory of Viral Heart Diseases, Chinese Academy of Medical Sciences, Fudan University, Shanghai, 200032, China

    18 shared publications
  • Xiang Wang

    Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, State Key Laboratory of Cardiovascular Diseases, NHC Key Laboratory of Ischemic Heart Diseases, and Institutes of Biomedical Sciences, Fudan University, Shanghai, China

    12 shared publications
  • Chao Yin

    Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, and Institutes of Biomedical Sciences, Fudan University, Shanghai, China

    10 shared publications
  • Chunjie Yang

    Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital and Institutes of Biomedical Sciences (J.W., Xuan Li, Xiang Li, J.J., L.K., L.C., C.Y., Z.Z., S.W., H.G., K.C., Y.Z.), Fudan University, China

    10 shared publications
  • Guoping Zhang

    Shanghai Institute of Cardiovascular Diseases, State Key Laboratory of Cardiovascular Diseases, Zhongshan Hospital, and Institutes of Biomedical Sciences, Fudan University, Shanghai, 200032, China

    9 shared publications

Latest Publications

  • TGF-β2 signaling promotes cardiac fibrosis in arrhythmogenic right ventricular cardiomyopathy mediated by DSC2 deficiency

    by Chen-Xing Huang, Ke-Jia Jin, Lan-Qing Xiang, Zhuo-Xin Lv, Ying Wang, Jian-Guo Jia, Fei-Zhen Wu, Yi-Zhun Zhu, Yun-Zeng Zou, Yu-Xiang Dai, et al.

    Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited cardiomyopathy characterized by progressive fibrofatty replacement of the right ventricular myocardium, ventricular arrhythmias, and an increased risk of sudden cardiac death. Pathogenic variants of desmosomal genes have been implicated in ARVC pathogenesis and may disrupt desmosomal protein function. However, whether and how desmosomal protein dysfunction directly activates cardiac fibroblasts to mediate fibrosis remains poorly understood. To address this, we combined genetic analysis with in vivo and cellular models to investigate the role of desmosomal dysfunction in cardiac fibrosis. The systematic genetic analysis revealed that desmosomal gene variants are predominant in ARVC, accounting for 67.4% of cases in cohort studies and 96.1% of pathogenic variants in ClinVar. We used desmocollin-2 (DSC2) knockout mice to recapitulate key features of ARVC, including right ventricular fibrosis, enlargement, and dysfunction. In vitro, DSC2 deficiency directly activates cardiac fibroblasts, resulting in increased cell proliferation, migration, and fibrosis marker expression. Further analysis identified transforming growth factor beta-2 (TGF-β2) as a critical signaling mediator in cardiac fibrosis of DSC2 deficiency-mediated ARVC. Mechanistically, DSC2 deficiency upregulated transcription factor 7 (TCF7) expression, promoting its binding to TGF-β2 promoter regions to enhance TGF-β2 transcription in cardiac fibroblasts. Pharmacological inhibition of TGF-β2 with pirfenidone (PFD) effectively attenuated cardiac fibrosis and improved right ventricular function in DSC2-deficient hearts. The results of the present study identified DSC2 deficiency-mediated TCF7-TGF-β2 signaling in cardiac fibroblasts, which contributed to ARVC development. Thus, targeting TGF-β2 signaling may be a promising therapeutic strategy for desmosome gene mutation-related ARVC.

  • Open Access

    Nucleosome assembly protein-like 1 degradation-dependent novel cardioprotection mechanism of Wnt2 against ischemia‒reperfusion injury

    by Ying Wang, Liming Chen, Jinyi Lin, Xi Liu, Kejia Jin, Chenxing Huang, Hao Wang, Jianguo Jia, Jian Wu, Zhiwen Ding, et al.

    Wnt and its crosstalk signaling pathways are involved in the modulating ischemia‒reperfusion (I/R) injury. However, whether Wnt2 is a novel therapeutic agent for I/R injury is largely unknown. Here, we show that the downregulation of serum Wnt2 levels in acute myocardial infarction (AMI) patients following reperfusion therapy, and Wnt2 levels are inversely correlated with the levels of myocardial injury markers (cTnT and CK-MB). Therapeutic administration of recombinant Wnt2 protein (rbWnt2) alleviates cardiac I/R injury and improves cardiac function by suppressing ROS levels and cardiomyocyte death in mice. Further analysis revealed that rbWnt2 downregulated Nap1L1 to reactivate the transcription of antioxidant genes (SOD, GPX, and UCP3) to reduce ROS levels and subsequently inhibit cardiomyocyte apoptosis and ferroptosis during the I/R process. Cardiac-specific Nap1L1 knockdown attenuated I/R injury, whereas overexpression of Nap1L1 partly abolished the cardiac protection mediated by rbWnt2 administration in the I/R model. Mechanistically, Wnt2 promoted Nap1L1 ubiquitination and degradation to restore ROS scavenging systems via Lrp6-mediated recruitment of the E3 ligase Trim11 in I/R hearts. Nap1L1 suppression plays a critical role in mediating the cardioprotective effects of rbWnt2. These findings establish Wnt2 as a therapeutic agent that targets compartmentalized oxidative damage, suggesting a novel strategy to mitigate I/R injury through the Lrp6/Trim11/Nap1L1 axis.


  • Minimally Invasive Model of Mitral Regurgitation in Mice

    by Jian Wu, Xuan Li, Xiang Li, Robert Lakin, Jieyun You, Jianguo Jia, Le Kang, Liming Chen, Chunjie Yang, Zhenzhong Zhang, et al.


  • Inflammation-Related Factors S100A9 and TLR2 in Cardiomyocyte Hypertrophy

    by Ke-Jia Jin, Le Pan, Chen-Xing Huang, Chao Yin, Ying Wang, Jie Zhang, Hui Gong

    Objective The pathogenesis and progression of heart failure (HF) are governed by complex, interconnected biological pathways, with dysregulated immune responses and maladaptive cardiac remodeling playing central roles. Although specific inflammatory mediators have been implicated in modulating critical features of cardiac remodeling—such as cardiomyocyte hypertrophy and extracellular matrix fibrosis—the precise molecular mechanisms driving these processes remain incompletely characterized. Methods Integrated bioinformatics analysis of HF and hypertrophic cardiomyopathy (HCM) transcriptomic datasets identified pathologically relevant candidate genes. A protein-protein interaction (PPI) network was constructed from these candidates using the STRING database, followed by module analysis. Serum S100 calcium-binding protein A9 (S100A9) protein expression in HF patients was quantified by Western blotting under reducing conditions. The functional relevance of prioritized genes was subsequently validated through: (i) in vitro cyclic mechanical stretch in primary neonatal rat cardiomyocytes, and (ii) in vivo pressure overload modeling via transverse aortic constriction (TAC) in mice. Results Bioinformatics analysis of HF and HCM datasets revealed a significant association between immune function and cardiac remodeling. Using CytoNCA, we identified core genes, among which the top 25 included multiple inflammatory pathway-related factors, such as S100A9 and Toll-like receptor 2 (TLR2). Notably, S100A9 levels were significantly elevated in the serum of HF patients and in mechanically stretched cardiomyocytes. This increase correlated with upregulated expression of hypertrophy-related markers, including atrial natriuretic peptide (ANP). Furthermore, mechanical stretch-induced S100A9 upregulation markedly enhanced TLR2 expression in cardiomyocytes. Importantly, TLR2 inhibition substantially attenuated the mechanical stretch-induced upregulation of S100A9 mRNA expression, as well as the subsequent hypertrophic and inflammatory responses in cardiomyocytes. Conclusion The inflammatory mediators S100A9 and TLR2 engage in reciprocal activation that amplifies the hypertrophic response in mechanically stretched cardiomyocytes. This pathogenic cross-talk exacerbates maladaptive remodeling and likely accelerates HF progression.


  • Open Access

    GSTM1 suppresses cardiac fibrosis post-myocardial infarction through inhibiting lipid peroxidation and ferroptosis

    by Kai-Jie Chen, Yue Zhang, Xin-Yi Zhu, Shuo Yu, Yao Xie, Cheng-Jiang Jin, Yi-Min Shen, Si-Yu Zhou, Xiao-Ce Dai, Sheng-An Su, et al.


  • Low-density lipoprotein receptor-related protein 6 ameliorates cardiac hypertrophy by regulating CTSD/HSP90α signaling during pressure overload

    by Le Pan, Chao Yin, Ke-Jia Jin, Chen-Xing Huang, Xiang Wang, Ying Wang, Suguro Rinkiko, Jian-Guo Jia, Guo-Ping Zhang, Yi-Zhun Zhu, et al.

    Pressure overload induces pathological cardiac remodeling, including cardiac hypertrophy and fibrosis, resulting in cardiac dysfunction or heart failure. Recently, we observed that the low-density lipoprotein receptor-related protein 6 (LRP6), has shown potential in enhancing cardiac function by mitigating cardiac fibrosis in a mouse model subjected to pressure overload. In this study, we investigated the role of LRP6 as a potential modulator of pressure overload-induced cardiac hypertrophy and elucidated the underlying molecular mechanisms. We performed transverse aortic constriction (TAC) to induce pressure overload in cardiomyocyte-specific LRP6 overexpression mice (LRP6-over mice) and in control mice (α-myosin heavy chain (α-MHC) Mer-Cre-Mer Tg mice or named MCM mice). Cardiac function and hypertrophy were assessed using echocardiography. LRP6-over mice showed improved cardiac function and reduced hypertrophy after TAC, compared with MCM mice. We also applied mechanical stretch to cultured neonatal rat cardiomyocytes to model pressure overload in vitro. Mass spectrometry analysis showed that LRP6 interacts with HSP90α and cathepsin D (CTSD) in cardiomyocytes under mechanical stress. Further analysis demonstrated that LRP6 facilitates CTSD-mediated degradation of HSP90α, consequently inhibiting β-catenin activation and reducing cardiac hypertrophy post-TAC. Treatment with recombinant HSP90α protein or the CTSD inhibitor, pepstatin A, partly abolished the protective effect of LRP6 overexpression on myocardial hypertrophy and cardiac function after TAC in mice. Collectively, our data suggest that LRP6 protects against pressure overload-induced myocardial remodeling and that the CTSD/HSP90α/β-catenin axis may be a potential therapeutic target.


  • Open Access

    Cardiac secreted HSP90α exacerbates pressure overload myocardial hypertrophy and heart failure

    by Le Pan, Chenxing Huang, Xuejuan Jin, Jian Wu, Kejia Jin, Jingyi Lin, Ying Wang, Jianxuan Li, Chao Yin, Xiang Wang, et al.


  • A Novel Method for Mitochondrial Membrane Potential Detection in Heart Tissue Following Ischemia-reperfusion in Mice

    by Chao Yin, Chen-Xing Huang, Le Pan, Ke-Jia Jin, Ying Wang, Meng-Ying Cao, Hong Lin, Pan Gao, Na Li, Hui Gong, et al.

    Objective Myocardial ischemia-reperfusion (I/R) injury is associated with a significant reduction in the mitochondrial membrane potential (MMP, ΔΨm). Fluorescence-based assays are effective for labelling active mitochondria in living cells; their application in heart tissue, however, represents a challenge because of a low yield of viable cardiomyocytes after cardiac perfusion. This study aimed to examine a novel method for detecting the changes in the MMP of mouse heart tissue following I/R injury. Methods The I/R model was established, which was characterized by distinct ischemic area and apoptosis in heart tissue. The MMP was detected via a confocal microscope after the ascending aorta was clamped and the mitochondrial probe solution (containing Mito-Tracker Deep Red FM) was perfused from the apex via a peristaltic pump. Results This method enabled the distribution of the probe solution throughout the cardiac tissue via the coronary circulation. Fluorescence detection revealed that the MMP was profoundly reduced in both ischemic area and border area following I/R when compared with that in the sham group. There was no obvious difference in the MMP of the remote area between the I/R group and the sham group. Conclusion This study presents a novel method for detecting the MMP in heart tissue, and this method will facilitate the evaluation of changes in the MMP in different regions following I/R.


  • Open Access

    Corrigendum to “Low density lipoprotein receptor related protein 6 (LRP6) protects heart against oxidative stress by the crosstalk of HSF1 and GSK3β” [Redox Biol. 37 (2020) 101699]

    by Ying Wang, Zhidan Chen, Yang Li, Leilei Ma, Yan Zou, Xiang Wang, Chao Yin, Le Pan, Yi Shen, Jianguo Jia, et al.

  • Optimization of Strategy for Modified mRNA Inducing Cardiac-Specific Expression in Mice

    by Chenxing Huang, Jianguo Jia, Kejia Jin, Yan Zou, Shudan Tan, Jing Lu, Yizhun Zhu, Jinzhong Lin, Yuxiang Dai, Hui Gong

    Lipid nanoparticle (LNP)-coated-modified RNA(modRNA) has been developed for enhancing the stability of modRNA, but it tends to accumulate in liver. The current study aimed to optimize strategy for increasing cardiac expression efficiency of modRNA. We synthesized Luciferase (Luc)-modRNA, and also developed 122Luc modRNA, a liver silencing Luc modRNA. Intramyocardial injection of naked Luc modRNA induced high bioluminescence signal in heart, but very low in other organs including liver. Luc modRNA-LNP injection showed the signal was increased by 5 folds in the heart and by 15,000 folds in the liver, compared to naked Luc modRNA group. In comparison with Luc modRNA-LNP group, the liver signal was decreased to 0.17%, while cardiac signal showed a slight drop by intramyocardial injection of 122Luc-modRNA-LNP. Our data revealed that intramyocardial injection of naked modRNA could effectively induced cardiac-specific expression. For cardiac delivery of Luc modRNA-LNP, 122modRNA-LNP enhances specificity of cardiac expression by abolishing liver signal.